Oncohematología y Genética

Terapias Avanzadas y Biomarcadores en Sarcomas (TERABIS)

Javier Martín Broto
Javier Martín Broto
IBiS
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n.
41013 · Sevilla
Laboratorio: 215

Javier Martín Broto

Volver al programa
  1. Miembros del grupo
  2. Áreas de trabajo
  3. Publicaciones

Grupo: Terapias Avanzadas y Biomarcadores en Sarcomas (TERABIS)

Directorio
Miembros del grupo Terapias Avanzadas y Biomarcadores en Sarcomas (TERABIS)
  • Acosta López, María José.Lda. en Biología
  • Amián Ruíz, Rubén.Ldo. en Biotecnología
  • Blanco Alcaina, Elena.Becaria GEIS
  • Carrasco García, Irene.MIR HUVR
  • da Silva Moura, David.Doctor en Ciencias Biológicas
  • Gavilán Naranjo, Angela María.Técnico de Apoyo. Doctora en Biotecnología
  • Hidalgo Ríos, Samuel.MIR HUVR
  • Hindi Muñiz, Nadia.Facultativo Especialista de Área. Investigadora Predoctoral.
  • Lacerenza, Serena.Doctora en Bioquímica y Biología Molecular
  • López Álvarez, María.Investigadora en Formación
  • Martín Broto , Javier.Dr. en Biomedicina. Adjunto de la Unidad de Oncología Médica. Hospital Universitario Virgen del Rocío.
  • Mondaza Hernández, José Lucinio.Investigador en formación. PFIS.
  • Sánchez Bustos, Paloma.Investigadora Predoctoral.
  • Santos Fernández, Paloma.Grado en Medicina. MIR. Estudiante de Doctorado.

Áreas de trabajo

El laboratorio de Terapias Avanzadas y Biomarcadores en Sarcomas (TERABIS; IR: Javier Martín Broto), conforma un equipo traslacional y pre-clínico integrado por oncólogos especializados en la clínica de sarcomas del Hospital Virgen del Rocío de Sevilla (Centro de Referencia Nacional y Europeo) y biólogos moleculares.

 Los objetivos principales del grupo son:

  • Probar nuevas combinaciones de fármacos en sarcomas
  • Identificar nuevas dianas terapéuticas en sarcomas
  • Identificar factores pronósticos y predictivos de respuesta a tratamiento en sarcomas.

 Para ello, el grupo diseña y participa en nuevos ensayos clínicos y pre-clínicos,  colaborando con entidades públicas y privadas, a nivel nacional e internacional.

 Al mismo tiempo, cuenta con modernas instalaciones para desarrollar sus propios estudios traslacionales, usando técnicas de biología  molecular y de análisis genómicos. Actualmente, nuestros esfuerzos preclínicos se centran en tres tipos de estudios principales:

           La realización de estudios genómicos basados en hibridaciones con microarrays y secuenciación de nueva generación (NGS) para identificar patrones moleculares relevantes para el desarrollo o tratamiento de los sarcomas.

-          El establecimiento de modelos in vitro con la creación de líneas celulares de sarcomasresistentes a fármacos.

-          El desarrollo de modelos PDX de ratón para estudiar, in vivo, .

 El laboratorio cuenta con financiación pública y privada en proyectos de investigación y lidera redes de trabajo y consorcios nacionales e internacionales (SELNET; H2020; https://selnet-h2020.org/).

 

MISION:

  • Dar racional para el desarrollo de ensayos clínicos mediante;
  • La exploración de nuevas combinaciones farmacológicas en sarcomas;
  • La Identificación de nuevas dianas terapéuticas relevantes en sarcoma;
  • Formación y docencia;
  • Publicación y presentaciones a congresos;
  • Tesis doctorales, trabajos fin de máster, trabajo fin de grado;
  • Aplicación a proyectos de investigación competitiva: regional, nacional e internacional;
  • Generar modelos PDX y nuevas líneas células;
  • Identifica factores pronósticos y predictivos de respuesta en sarcoma;
  • Nuevas técnicas;
  • Desarrollar proyectos de investigación clínica y traslacional independientes;
  • Trabajo en red.

  VISION:

  • Posibilitar nuevos fármacos o mejoras en sarcomas;
  • Mejorar la calidad de vida en pacientes;
  • Mejorar la supervivencia;
  • Mejorar la estratificación molecular pronostica y predictiva;
  • Optimizar la secuencia terapéutica;
  • Sostenibilidad financiera del grupo;
  • Mejorar como grupo y red;
  • Foco en sarcoma;
  • Estrategia;
  • Establecer redes de trabajo.

 VALORES:

  • Ética profesional;
  • Autocrítica;
  • Compromiso/esfuerzo;
  • Solidaridad/compañerismo;
  • Reciprocidad;
  • Generosidad;
  • Entusiasmo e ilusión;
  • Empatía.

 

 

 

Revistas Internacionales
Martin-Broto, J; Hindi, N; Lopez-Pousa, A; Peinado-Serrano, J; Alvarez, R; Alvarez-Gonzalez, A; Italiano, A; Sargos, P; Cruz-Jurado, J; Isern-Verdum, J; Dolado, MC; Rincon-Perez, I; Sanchez-Bustos, P; Gutierrez, A; Romagosa, C; Morosi, C; Grignani, G; Gatti, M; Luna, P; Alastuey, I; Redondo, A; Belinchon, B; Martinez-Serra, J; Sunyach, MP; Coindre, JM; Dei Tos, AP; Romero, J; Gronchi, A; Blay, JY; Moura, DS
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas A Nonrandomized Phase 1/2 Clinical Trial
JAMA ONCOLOGY
Tap, WD; Wagner, AJ; Schoffski, P; Martin-Broto, J; Krarup-Hansen, A; Ganjoo, KN; Yen, CC; Razak, AAR; Spira, A; Kawai, A; Le Cesne, A; Van Tine, BA; Naito, Y; Park, SH; Fedenko, A; Papai, Z; Soldatenkova, V; Shahir, A; Mo, G; Wright, J; Jones, RL
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
D'Ambrosio, L; Touati, N; Blay, JY; Grignani, G; Flippot, R; Czarnecka, AM; Piperno-Neumann, S; Martin-Broto, J; Sanfilippo, R; Katz, D; Duffaud, F; Vincenzi, B; Stark, DP; Mazzeo, F; Tuchscherer, A; Chevreau, C; Sherriff, J; Estival, A; Litiere, S; Sents, W; Ray-Coquard, I; Tolomeo, F; Le Cesne, A; Rutkowski, P; Stacchiotti, S; Kasper, B; Gelderblom, H; Gronchi, A
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
CANCER
Demetri, GD; Antonescu, CR; Bjerkehagen, B; Bovee, JVMG; Boye, K; Chacon, M; Dei Tos, AP; Desai, J; Fletcher, JA; Gelderblom, H; George, S; Gronchi, A; Haas, RL; Hindi, N; Hohenberger, P; Joensuu, H; Jones, RL; Judson, I; Kang, YK; Kawai, A; Lazar, AJ; Le Cesne, A; Maestro, R; Maki, R; Martin, J; Patel, S; Penault-Llorca, F; Raut, CP; Rutkowski, P; Safwat, A; Sbaraglia, M; Schaefer, IM; Shen, L; Serrano, C; Schoffski, P; Stacchiotti, S; Hall, KS; Tap, WD; Thomas, DM; Trent, J; Valverde, C; van der Graaf, WTA; von Mehren, M; Wagner, A; Wardelmann, E; Naito, Y; Zalcberg, J; Blay, JY
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
ANNALS OF ONCOLOGY
Radaelli, S; Fossati, P; Stacchiotti, S; Akiyama, T; Asencio, JM; Bandiera, S; Boglione, A; Boland, P; Bolle, S; Bruland, O; Brunello, A; Bruzzi, P; Campanacci, D; Cananzi, F; Capanna, R; Casadei, R; Cordoba, A; Court, C; Dei Tos, AP; DeLaney, TF; De Paoli, A; De Pas, TM; Desai, A; Di Brina, L; Donati, DM; Fabbri, N; Fiore, MR; Frezza, A; Gambarotti, M; Gasbarrini, A; Georg, P; Grignani, G; Hindi, N; Hug, EB; Jones, R; Kawai, A; Krol, AD; Le Grange, F; Luzzati, A; Marquina, G; Martin-Benlloch, JA; Mazzocco, K; Navarria, F; Navarria, P; Parchi, PD; Patel, S; Pennacchioli, E; Petrongari, MG; Picci, P; Pollock, R; Porcu, L; Quagliuolo, V; Sangalli, C; Scheipl, S; Scotto, GM; Spalek, M; Steinmeier, T; Timmermann, B; Trama, A; Uhl, M; Valverde, C; Varga, PP; Verges, R; Weber, DC; Zoccali, C; Casali, PG; Sommer, J; Gronchi, A
The sacral chordoma margin
EJSO
Martin-Broto, J; Cruz, J; Penel, N; Le Cesne, A; Hindi, N; Luna, P; Moura, DS; Bernabeu, D; de Alava, E; Lopez-Guerrero, JA; Dopazo, J; Pena-Chilet, M; Gutierrez, A; Collini, P; Karanian, M; Redondo, A; Lopez-Pousa, A; Grignani, G; Diaz-Martin, J; Marcilla, D; Fernandez-Serra, A; Gonzalez-Aguilera, C; Casali, PG; Blay, JY; Stacchiotti, S
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial
LANCET ONCOLOGY
Perez, M; Garcia-Heredia, JM; Felipe-Abrio, B; Munoz-Galvan, S; Martin-Broto, J; Carnero, A
Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment
SIGNAL TRANSDUCTION AND TARGETED THERAPY
Martin-Broto, J; Reichardt, P; Jones, RL; Stacchiotti, S
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype
EXPERT REVIEW OF ANTICANCER THERAPY
Gonzalez, LMD; Martin-Broto, J; Kasper, B; Blay, JY; Le Cesne, A
Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma
EXPERT REVIEW OF ANTICANCER THERAPY
Martin-Broto, J; Moura, DS
New drugs in gastrointestinal stromal tumors
CURRENT OPINION IN ONCOLOGY
Napolitano, A; Provenzano, S; Colombo, C; Vitellaro, M; Brunello, A; Badalamenti, G; Nannini, M; Ibrahim, T; Hohenberger, P; Gasperoni, S; Gennatas, S; Jones, RL; Hindi, N; Martin-Broto, J; Ceruso, MS; Silletta, M; Tos, APD; Gronchi, A; Stacchiotti, S; Santini, D; Tonini, G; Palassini, E; Vincenzi, B
Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis
ESMO OPEN
Constantinidou, A; Sauve, N; Stacchiotti, S; Blay, JY; Vincenzi, B; Grignani, G; Rutkowski, P; Guida, M; Hindi, N; Klein, A; Thibaud, V; Sufliarsky, J; Desar, I; Steeghs, N; Litiere, S; Gelderblom, H; Jones, RL
Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study
ESMO OPEN
Martin-Broto, J; Hindi, N; Grignani, G; Martinez-Trufero, J; Redondo, A; Valverde, C; Stacchiotti, S; Lopez-Pousa, A; D'Ambrosio, L; Gutierrez, A; Perez-Vega, H; Encinas-Tobajas, V; de Alava, E; Collini, P; Pena-Chilet, M; Dopazo, J; Carrasco-Garcia, I; Lopez-Alvarez, M; Moura, DS; Lopez-Martin, JA
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Martin-Broto, J; Moura, DS; Van Tine, BA
Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas
CLINICAL CANCER RESEARCH
Serrano, C; Vivancos, A; Lopez-Pousa, A; Matito, J; Mancuso, FM; Valverde, C; Quiroga, S; Landolfi, S; Castro, S; Dopazo, C; Sebio, A; Virgili, AC; Menso, MM; Martin-Broto, J; Sanso, M; Garcia-Valverde, A; Rosell, J; Fletcher, JA; George, S; Carles, J; Arribas, J
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
BMC CANCER
Anderton, J; Moroz, V; Marec-Berard, P; Gaspar, N; Laurence, V; Martin-Broto, J; Sastre, A; Gelderblom, H; Owens, C; Kaiser, S; Fernandez-Pinto, M; Fenwick, N; Evans, A; Strauss, S; Whelan, J; Wheatley, K; Brennan, B
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol
TRIALS
Gronchi, A; Palmerini, E; Quagliuolo, V; Broto, JM; Pousa, AL; Grignani, G; Brunello, A; Blay, JY; Tendero, O; Diaz Beveridge, R; Ferraresi, V; Lugowska, I; Merlo, DF; Fontana, V; Marchesi, E; Braglia, L; Donati, DM; Palassini, E; Bianchi, G; Marrari, A; Morosi, C; Stacchiotti, S; Bague, S; Coindre, JM; Dei Tos, AP; Picci, P; Bruzzi, P; Casali, PG
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups
JOURNAL OF CLINICAL ONCOLOGY
Martin-Broto, J; Hindi, N; Aguiar, S; Badilla-Gonzalez, R; Castro-Oliden, V; Chacon, M; Correa-Generoso, R; de Alava, E; Donati, DM; Eriksson, M; Falla-Jimenez, M; German, G; Silva, MLG; Gouin, F; Gronchi, A; Haro-Varas, JC; Jimenez-Brenes, N; Kasper, B; de Mello, CAL; Maki, R; Martinez-Delgado, P; Martinez-Said, H; Martinez-Tlahuel, JL; Morales-Perez, JM; Munoz-Casares, FC; Nakagawa, SA; Ortiz-Cruz, EJ; Palmerini, E; Patel, S; Moura, DS; Stacchiotti, S; Sunyach, MP; Valverde, CM; Waisberg, F; Blay, JY
Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic
ONCOLOGIST
Kamposioras, K; Mauri, D; Papadimitriou, K; Anthoney, A; Hindi, N; Petricevic, B; Dambrosio, M; Valachis, A; Kountourakis, P; Kopecky, J; Kuhar, CG; Popovic, L; Chilingirova, NP; Zarkavelis, G; de Mello, RA; Plavetic, ND; Christopoulos, C; Mostert, B; Goffin, JR; Tzachanis, D; Saraireh, HH; Ma, F; Pavese, I; Tolia, M
Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth
FRONTIERS IN ONCOLOGY
Moura, DS; Sanchez-Bustos, P; Fernandez-Serra, A; Lopez-Alvarez, M; Mondaza-Hernandez, JL; Blanco-Alcaina, E; Gavilan-Naranjo, A; Martinez-Delgado, P; Lacerenza, S; Santos-Fernandez, P; Carrasco-Garcia, I; Hidalgo-Rios, S; Gutierrez, A; Ramos, R; Hindi, N; Taron, M; Lopez-Guerrero, JA; Martin-Broto, J
CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study
CANCERS
Martinez-Font, E; Perez-Capo, M; Ramos, R; Felipe, I; Garcias, C; Luna, P; Terrasa, J; Martin-Broto, J; Vogler, O; Alemany, R; Obrador-Hevia, A
Impact of Wnt/beta-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas
CANCERS
Fernandez-Serra, A; Moura, DS; Sanchez-Izquierdo, MD; Calabuig-Farinas, S; Lopez-Alvarez, M; Martinez-Martinez, A; Carrasco-Garcia, I; Ramirez-Calvo, M; Blanco-Alcaina, E; Lopez-Reig, R; Obrador-Hevia, A; Alemany, R; Gutierrez, A; Hindi, N; Poveda, A; Lopez-Guerrero, JA; Martin-Broto, J
Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study
CANCERS
Hindi, N; Garcia, IC; Sanchez-Camacho, A; Gutierrez, A; Peinado, J; Rincon, I; Benedetti, J; Sancho, P; Santos, P; Sanchez-Bustos, P; Marcilla, D; Encinas, V; Chacon, S; Munoz-Casares, C; Moura, D; Martin-Broto, J
Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
CANCERS
Martinez-Delgado, P; Lacerenza, S; Obrador-Hevia, A; Lopez-Alvarez, M; Mondaza-Hernandez, JL; Blanco-Alcaina, E; Sanchez-Bustos, P; Hindi, N; Moura, DS; Martin-Broto, J
Cancer Stem Cells in Soft-Tissue Sarcomas
CELLS
Stacchiotti S, Ferrari S, Redondo A, Hindi-Muniz N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J.
Pazopanib for f advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial
Lancet Oncol.
Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J.
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Lancet Oncol
Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J.
Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.
Clin Cancer Res.
Moura DS, Ramos R, Fernandez-Serra A, Serrano T, Cruz J, Alvarez-Alegret R, Ortiz-Duran R, Vicioso L, Gomez-Dorronsoro ML, Garcia Del Muro X, Martinez-Trufero J, Rubio-Casadevall J, Sevilla I, Lainez N, Gutierrez A, Serrano C, Lopez-Alvarez M, Hindi N, Taron M, López-Guerrero JA, Martin-Broto J.
Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
Oncotarget
Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Moura DS, Luna P, Hindi N, Lopez-Pousa A.
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Ann Oncol
Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A.J
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.
J Clin Oncol